IMCD reports EBITA of EUR 127 million in the first three months of 2024
26 April 2024 - 7:00AM
IMCD reports EBITA of EUR 127 million in the first three months of
2024
Rotterdam, The Netherlands (26 April 2024) -
IMCD N.V. (“IMCD” or “Company”), a global leading distribution
partner, and formulator of speciality chemicals and ingredients,
today announces its first three months 2024 results.
HIGHLIGHTS
- Gross profit of EUR 295 million (on a constant currency basis,
equal to the first three months of 2023)
- Operating EBITA decline of 15% to EUR 127 million (-13% on a
constant currency basis)
- Free cash flow of EUR 106 million (first three months of 2023:
EUR 147 million)
- Cash earnings per share decline of 19% to EUR 1.41 (first three
months of 2023: EUR 1.74)
- Successful completion of six acquisitions: Valuetree and CJ
Shah in India, Joli Foods in Colombia, RBD in China, Euro
Chemo-Pharma/Biofresh in Malaysia and Gova in the Benelux
Valerie Diele-Braun, CEO: "In a volatile first quarter of the
year, we faced challenging conditions in some of our market
segments, resulting in a lower operating EBITA of EUR 127 million
versus a very strong Q1 2023. Whilst our acquisition pipeline and
projects with principals and customers remain healthy in all
regions, current market dynamics continue to make future customer
demand difficult to predict. Our strong commercial teams, digital
and logistics infrastructure, combined with further driving
operational excellence and cost control, will deliver future growth
and efficiencies."
Attached, the full press release in PDF format and the main
visual.
- PR_IMCD NV first three months of 2024 results
- IMCD_logo
IMCD NV (EU:IMCD)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
IMCD NV (EU:IMCD)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
